{"preliminary_commentary":{"by_channel":{"x_thread":9},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05255302\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"DIAL","nct_id":"NCT05255302","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dial-nct05255302. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DIAL","arms":[{"description":"6 months treatment by chemotherapy + pembrolizumab followed by pembrolizumab ± pemetrexed for patients with non-squamous cell carcinoma (SCC) until 2 years max","label":"Arm A : control Arm","type":"ACTIVE_COMPARATOR"},{"description":"6 months treatment by chemotherapy + pembrolizumab followed by pemetrexed for patients with non-SCC or observation for patients with SCC","label":"Arm B : experimental arm","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-06-01","type":"ESTIMATED"},"conditions":["Metastatic NSCLC"],"enrollment":{"count":1360,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab before randomization","otherNames":[],"type":"DRUG"},{"name":"Chemotherapy","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab after randomization","otherNames":[],"type":"DRUG"}],"last_update":"2025-04-01","lead_sponsor":"Intergroupe Francophone de Cancerologie Thoracique","official_title":"A Phase II-III Randomized Trial Evaluating Maintenance Pembrolizumab (± Pemetrexed) Until Progression Versus Observation (± Pemetrexed) After 6 Months of Platinum-based Doublet Chemotherapy Plus Pembrolizumab Induction Treatment in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2025-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase II: 18-month overall survival (OS)","timeFrame":"18 months after inclusion"},{"measure":"Phase III: overall survival","timeFrame":"about 24 months after randomization"}],"references":[],"start_date":{"date":"2022-05-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction","url":"https://clinicaltrials.gov/study/NCT05255302"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dial-nct05255302"}